Last reviewed · How we verify
NCT03500471
Robotic and Laparoscopic Total Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer
trial testing Robotic-assisted Total Gastrectomy in Gastric Cancer in 142 participants. Completed in 30 August 2021.
30 August 2021
Quick facts
| Lead sponsor | Southwest Hospital, China |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 142 |
| Start date | 16 April 2018 |
| Primary completion | 30 August 2021 |
| Estimated completion | 30 August 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Robotic-assisted Total Gastrectomy
- Laparoscopic-assisted Total Gastrectomy
Conditions studied
- Gastric Cancer — all drugs for Gastric Cancer →
Sponsor
Southwest Hospital, China
Who can join
Adults 18 to 80, any sex, with Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a prospective, single-center, non-randomized, controlled, non-blind, and non-inferiority observation trial comparing robotic-assisted total gastrectomy with D2 lymph nodal dissection for locally advanced gastric cancer patients with laparoscopic procedure.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Current clinical trials on gastric cancer surgery in China.
Zhang S, Hu RH, Cui XM, Song C, et al · · 2024 · PMID 39554743 · DOI 10.4251/wjgo.v16.i11.4369
Verify or expand the search:
- PubMed search for NCT03500471
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Cancer
Currently open trials in the same condition.
- NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
Other Southwest Hospital, China trials
Trials by the same sponsor.
- NCT07469293 — Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke · Phase 3 · not yet recruiting
- NCT07294209 — Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients · Phase 4 · recruiting
- NCT07251374 — Osteomyelitis Multi-center Prospective Cohort Study · not yet recruiting
- NCT06894433 — Efficacy and Safety of NeuroEndoscopic Surgery for Large IntraCerebral Hemorrhage · NA · recruiting
- NCT06791538 — Robotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03500471 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Southwest Hospital, China
- Last refreshed: 21 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03500471.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing